Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Resistance Bacterial, Morality, Child Health, Implementation
Interventions: Azithromycin for Oral Suspension; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month and older
Enrollment: 169,707 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen; Diagnostic Test
Lead sponsor: Haemonetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Oakland, California • Maywood, Illinois • New Orleans, Louisiana

Conditions: Rett Syndrome
Interventions: Sarizotan low dose, Sarizotan high dose, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 4 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Birmingham, Alabama • San Diego, California • Chicago, Illinois + 2 more

Conditions: Shoulder Pain, Opioid Use
Interventions: Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cerebral Palsy, Scoliosis
Interventions: Not listed
Lead sponsor: Setting Scoliosis Straight Foundation; Other
Eligibility: 8 Years to 21 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 12
States / cities: San Diego, California • Wilmington, Delaware • Miami, Florida + 7 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 1 Month to 12 Months
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more

Conditions: Dehydration
Interventions: Not listed
Lead sponsor: Arizona State University; Other
Eligibility: 3 Years to 13 Years
Enrollment: 1,454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stress Disorders, Post-Traumatic, Depression, Antisocial Personality Disorder, Anxiety, Aggressive Behavior
Interventions: RRF4H Combination Intervention; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 14 Years to 17 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Stroke, Multiple Sclerosis
Interventions: Visuomotor leg reaching task; Behavioral
Lead sponsor: Texas Woman's University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 130 participants
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 50
States / cities: Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more

Conditions: Meditation, Control Group
Interventions: Calm Meditation, Educational Podcast Control; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 40 Years to 64 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Influenza A
Interventions: AZD4117, AZD5315, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more

Conditions: Parkinson Disease
Interventions: Multimodal overground locomotor training; Other
Lead sponsor: George Mason University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: REGN910-3, Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more

Conditions: Influenza
Interventions: FluLaval™ Quadrivalent, Fluzone® Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 2,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Talaporfin Sodium (LS11) Photodynamic Therapy (PDT); Drug
Lead sponsor: Light Sciences LLC; Industry
Eligibility: 50 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Anemia, Venous Thrombosis
Interventions: blood sampling; Other
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more

Conditions: Psoriasis
Interventions: Saliva or buccal sample; Other
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid Use Disorder
Interventions: Neurocognitive battery, fNIRS; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 192 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Childhood
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 9 Years to 11 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Prediabetes, Overweight, Obesity
Interventions: Prevent; Behavioral
Lead sponsor: Omada Health, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • San Fernando, California • Monroe, Washington

Conditions: Suicide, Suicidal Ideation
Interventions: STAT-PC, YST-III; Other
Lead sponsor: Elizabeth Arnold; Other
Eligibility: 18 Years to 24 Years
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Austin, Texas • Dallas, Texas

Conditions: Social Disconnection
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 55 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Multimodal Analgesia in Shoulder Arthroplasty

Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Reference Values and Determinants of Hydration in Children 3-13 y

Resettled Refugee Families for Healing

Motor Skill Acquisition Between Individuals With Neurological Disorders and Healthy Individuals

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

A Brief App-based Mobile Health and Well-being Intervention Among Middle-aged Adults

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Effect of Multimodal Exercise Training on Walking Economy in Individuals With Parkinson's Disease

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

Utilization of TEG to Monitor Rivaroxaban Activity

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Genetic Analysis of Pediatric Psoriasis

Integrating Brain, Neurocognitive, and Computational Tools in OUD

Impact of Hypothalamic Gliosis on Appetite Regulation and Obesity Risk in Children

Evaluation of Prevent in Underserved Populations

Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care

Social Disconnection Study